Expression of p53 isoforms in renal cell carcinoma

Chinese Medical Journal

Volumn 122, Issue 8, 2009, Pages 921-926

  Song, Wei ^a   Huo, Shi Wei ^b   Lü, Jia Ju ^a   Liu, Zheng ^a   Fang, Xiao Lei ^b   Jin, Xun Bo ^a   Yuan, Ming Zhen ^b  

^a SHANDONG UNIVERSITY   (China)

^b Key Laboratory of Cardiovascular Proteomics of Shandong Province   (China)

Author keywords

Alternative splicing; p53; Renal cell carcinoma; Tumour stage

Indexed keywords

ISOPROTEIN; MESSENGER RNA; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR GROWTH; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 68249138155     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.08.008     Document Type: Article

References (31)

1. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-263,
2. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52.
3. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18: 7621-7636.
4. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001; 1: 233-240.
5. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-316.
6. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-819.
7. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19: 2122-2137.
8. Baumbusch LO, Myhre S, Langerod A, Bergamaschi A, Geisler SB, Lonning PE, et al. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer 2006; 5: 47.
9. Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E, et al. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res 2006; 34: 5603-5612.
10. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 2006; 12: 3985-3992.
11. Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 2007; 43: 617-623.
12. Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int 2001; 88: 818-824.
13. Zhang J, Huang YR, Liu DM, Zhou LX, Xue W, Chen Q, et al. Management of solid renal tumour associated with von Hippel-Lindau disease. Chin Med J 2007; 120: 2049-2052.
14. Guimaraes DP, Hainaut P. TP53: a key gene in human cancer. Biochimie 2002; 84: 83-93.
15. Girgin C, Tarhan H, Hekimgil M, Sezer A, Gurel G. P53 mutations and other prognostic factors of renal cell carcinoma. Urol Int 2001; 66: 78-83.
16. Contractor H, Zariwala M, Bugert P, Zeisler J, Kovacs G. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol 1997; 181: 136-139.
17. Dijkhuizen T, Van den Berg E, Van den Berg A, Storkel S, De Jong B, Seitz G, et al. Chromosomal findings and p53-mutation analysis in chromophilic renal-cell carcinomas. Int J Cancer 1996; 68: 47-50.
18. Michael A, Pandha HS. Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol 2003; 4: 215-223.
19. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663.
20. Stephen CW, Helminen P, Lane DP. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol 1995; 248: 58-78.
21. Vojtesek B, Dolezalova H, Lauerova L, Svitakova M, Havlis P, Kovarik J, et al. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene 1995; 10: 389-393.
22. Caceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 2002; 18: 186-193.
23. Saltzman AL, Kim YK, Pan Q, Fagnani MM, Maquat LE, Blencowe BJ. Regulation of multiple core spliceosomal proteins by alternative splicing-coupled nonsense-mediated mRNA decay. Mol Cell Biol 2008; 28: 4320-4330.
24. Kim E, Goren A, Ast G. Alternative splicing and disease. RNA Biol 2008; 5: 17-19.
25. Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 2004; 24: 7987-7997.
26. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006; 13: 962-972.
27. Tomasino RM, Morello V, Tralongo V, Nagar C, Nuara R, Daniele E, et al. p53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization. Pathologica 1994; 86: 227-233.
28. Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 2000; 6: 1840-1844.
29. Pietsch EC, Sykes SM, McMahon SB, Murphy ME. The p53 family and programmed cell death. Oncogene 2008; 27: 6507-6521.
30. Goldschneide D, Horvilleur E, Plassa LF, Bataille MG, Million K, Wittmer-Dupret E, et al. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucl Acids Res 2006; 34: 5603-5612.
31. Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP, et al. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 2008; 14: 1659-1668.